Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma
Yuri Sakaguchi, Takaya Komori, Megumi Aoki and 3 more
Acta Dermato-Venereologica · 2020
doi:10.2340/00015555-3681 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Photosensitive dermatitis is clinically recognized as sunlight-induced dermatitis.It develops through 2 mechanisms: phototoxicity and photoallergy.Of these, photoallergic dermatitis is a type IV hypersensitive photoreaction against an external or internal antigen, which is mediated largely by ultraviolet A (UVA) (1, 2).Although various antigens, including antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) are reported to induce photosensitivity (1), there is no report that indicates the possibility of immune checkpoint inhibitor-associated photosensitivity.We report here a case of photosensitive dermatitis possibly induced by nivolumab/ipilimumab combination therapy (NIV/IPI) in a patient with malignant melanoma. CASE REPORTA 64-year-old, previously healthy, male developed nail apparatus melanoma of the right thumb (Fig. 1a).He underwent wide local excision and sentinel lymph node biopsy.Histological examination showed no evidence of metastasis and he was followed up carefully.After 7 months, positron-emission tomography/computed tomography revealed multiple metastases in the brain.Soon after gamma knife treatment (24 Gy/1 Fr) for brain metastases, NIV/ IPI therapy was initiated.One week after the first NIV/IPI therapy, red, palpable papules appeared on the patient's trunk, and he was treated with topical difluprednate ointment.Immediately after the second NIV/IPI therapy, the erythema augmented and was predominantly localized in the sun-exposed area (Fig. 1b).Photo-tests showed a markedly decreased minimal erythema dose (MED) of 3 J/cm 2 UVA.No obvious decreases in the MED of UVB or visible light
Abstract licence: CC BY-NC
References5
5 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.